Sutro Biopharma Stock Market Outlook
| STRO Stock | USD 19.68 0.87 4.23% |
About 64% of all Sutro Biopharma's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Sutro Biopharma suggests that some traders are interested. Sutro Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Sutro Biopharma. Many technical investors use Sutro Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 64
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Sutro Biopharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Sutro Biopharma.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Sutro Biopharma is 'Strong Hold'. The recommendation algorithm takes into account all of Sutro Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
Execute Sutro Biopharma Advice
The Sutro recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Sutro Biopharma. Macroaxis does not own or have any residual interests in Sutro Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sutro Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Solid | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Sutro Biopharma has a Risk Adjusted Performance of 0.1927, Jensen Alpha of 1.34, Total Risk Alpha of 0.902, Sortino Ratio of 0.2401 and Treynor Ratio of 0.7929Our advice tool can cross-verify current analyst consensus on Sutro Biopharma and to analyze the firm potential to grow in the current economic cycle. To make sure Sutro Biopharma is not overpriced, please validate all Sutro Biopharma fundamentals, including its book value per share, and the relationship between the net income and number of employees . Given that Sutro Biopharma has a number of shares shorted of 645.07 K, we advise you to double-check Sutro Biopharma market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.
Sutro Biopharma Trading Alerts and Improvement Suggestions
| Sutro Biopharma is way too risky over 90 days horizon | |
| Sutro Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 274.15 M. | |
| Sutro Biopharma currently holds about 225.64 M in cash with (191.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33. | |
| Sutro Biopharma has a strong financial position based on the latest SEC filings | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Sutro Biopharma Announces Participation at the 16th World ADC London Summit |
Sutro Biopharma Returns Distribution Density
The distribution of Sutro Biopharma's historical returns is an attempt to chart the uncertainty of Sutro Biopharma's future price movements. The chart of the probability distribution of Sutro Biopharma daily returns describes the distribution of returns around its average expected value. We use Sutro Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sutro Biopharma returns is essential to provide solid investment analysis for Sutro Biopharma.
| Mean Return | 1.49 | Value At Risk | -7.78 | Potential Upside | 11.87 | Standard Deviation | 6.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sutro Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sutro Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Sutro Biopharma, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Sutro Biopharma back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Vanguard Group Inc | 2025-12-31 | 375.8 K | Aqr Capital Management Llc | 2025-09-30 | 354.4 K | Fisher Asset Management, Llc | 2025-09-30 | 352.9 K | State Street Corp | 2025-09-30 | 342.7 K | Royal Bank Of Canada | 2025-09-30 | 259 K | Vestal Point Capital Lp | 2025-12-31 | 243 K | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 241.9 K | Balyasny Asset Management Llc | 2025-12-31 | 230 K | Samsara Biocapital, Llc | 2025-12-31 | 204.5 K | Millennium Management Llc | 2025-09-30 | 4.5 M | Acadian Asset Management Llc | 2025-09-30 | 3.4 M |
Sutro Biopharma Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (82.0M) | (35.0M) | (18.3M) | 218.5M | 251.3M | 263.8M | |
| Change In Cash | (175.7M) | 16.8M | 22.0M | 121.0M | 139.2M | 146.1M | |
| Free Cash Flow | (97.0M) | (4.3M) | (115.9M) | (194.6M) | (175.2M) | (166.4M) | |
| Depreciation | 4.8M | 5.7M | 6.8M | 7.2M | 8.3M | 6.0M | |
| Other Non Cash Items | 6.2M | (13.6M) | (2.2M) | (4.9M) | (4.4M) | (4.2M) | |
| Capital Expenditures | 15.3M | 7.9M | 4.3M | 3.1M | 3.6M | 6.2M | |
| Net Income | (105.5M) | (119.2M) | (106.8M) | (227.5M) | (204.7M) | (194.5M) | |
| End Period Cash Flow | 31.3M | 48.1M | 70.1M | 191.2M | 219.8M | 230.8M | |
| Change To Netincome | 10.7M | (28.5M) | 36.6M | 12.7M | 14.6M | 15.3M |
Sutro Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sutro Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sutro Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sutro stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.34 | |
β | Beta against Dow Jones | 1.86 | |
σ | Overall volatility | 5.58 | |
Ir | Information ratio | 0.23 |
Sutro Biopharma Volatility Alert
Sutro Biopharma is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sutro Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sutro Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sutro Biopharma Fundamentals Vs Peers
Comparing Sutro Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sutro Biopharma's direct or indirect competition across all of the common fundamentals between Sutro Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sutro Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sutro Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sutro Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sutro Biopharma to competition |
| Fundamentals | Sutro Biopharma | Peer Average |
| Return On Equity | -18.1 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Profit Margin | (2.05) % | (1.27) % |
| Operating Margin | (4.01) % | (5.51) % |
| Current Valuation | 185.52 M | 16.62 B |
| Shares Outstanding | 85.14 M | 571.82 M |
| Shares Owned By Insiders | 4.68 % | 10.09 % |
| Shares Owned By Institutions | 67.55 % | 39.21 % |
| Number Of Shares Shorted | 645.07 K | 4.71 M |
| Price To Earning | 53.08 X | 28.72 X |
| Price To Book | 2.11 X | 9.51 X |
| Price To Sales | 3.18 X | 11.42 X |
| Revenue | 62.04 M | 9.43 B |
| Gross Profit | 274.15 M | 27.38 B |
| EBITDA | (180.45 M) | 3.9 B |
| Net Income | (227.46 M) | 570.98 M |
| Cash And Equivalents | 225.64 M | 2.7 B |
| Cash Per Share | 4.33 X | 5.01 X |
| Total Debt | 23.15 M | 5.32 B |
| Debt To Equity | 0.27 % | 48.70 % |
| Current Ratio | 7.44 X | 2.16 X |
| Book Value Per Share | (1.02) X | 1.93 K |
| Cash Flow From Operations | (191.54 M) | 971.22 M |
| Short Ratio | 2.37 X | 4.00 X |
| Earnings Per Share | (2.60) X | 3.12 X |
| Price To Earnings To Growth | 0.12 X | 4.89 X |
| Target Price | 2.69 | |
| Number Of Employees | 178 | 18.84 K |
| Beta | 1.61 | -0.15 |
| Market Capitalization | 79.09 M | 19.03 B |
| Total Asset | 387.21 M | 29.47 B |
| Retained Earnings | (786.87 M) | 9.33 B |
| Working Capital | 211.42 M | 1.48 B |
Note: Acquisition by Petree Daniel H of 1500 shares of Sutro Biopharma at 10.38 subject to Rule 16b-3 [view details]
Sutro Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sutro . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 19.68 | |||
| Day Typical Price | 19.68 | |||
| Price Action Indicator | (0.44) | |||
| Period Momentum Indicator | (0.87) | |||
| Relative Strength Index | 22.17 |
Sutro Biopharma Target Price Consensus
Sutro target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Sutro Biopharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Buy |
Most Sutro analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Sutro stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Sutro Biopharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSutro Biopharma Target Price Projection
Sutro Biopharma's current and average target prices are 19.68 and 2.69, respectively. The current price of Sutro Biopharma is the price at which Sutro Biopharma is currently trading. On the other hand, Sutro Biopharma's target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Sutro Biopharma Market Quote on 3rd of March 2026
Target Price
Analyst Consensus On Sutro Biopharma Target Price
Sutro Biopharma Analyst Ratings
Sutro Biopharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Sutro Biopharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Sutro Biopharma's financials, market performance, and future outlook by experienced professionals. Sutro Biopharma's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Sutro Biopharma Buy or Sell Advice
When is the right time to buy or sell Sutro Biopharma? Buying financial instruments such as Sutro Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sutro Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sutro Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.